Advertisement
News
Advertisement

InVivo Therapeutics appoints Hess as CSO

Tue, 09/18/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Just months after joining InVivo Therapeutics Holdings Corp. (OTCBB: NVIV) as director of product development, Brian Hess has been appointed interim chief scientific officer of the Cambridge developer of technology for the treatment of neurotrauma and spinal cord injuries.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading